How to Finance an Independent Pharmacy Acquisition

From SBA 7(a) loans to seller carry and equity co-investment, here are the capital structures buyers use to close pharmacy deals in the $1M–$5M revenue range.

Find Pharmacy Deals SBA Calculator →

Financing an independent pharmacy acquisition requires navigating pharmacy-specific lender requirements, DEA transfer timelines, and prescription file valuation. Most lower middle market pharmacy deals combine SBA 7(a) debt with seller carry and modest buyer equity, with lenders scrutinizing PBM reimbursement trends, DIR fee exposure, and active patient refill rates before committing capital.

Financing Options for Pharmacy Acquisitions

SBA 7(a) Loan

$500K–$5MPrime + 2.25%–2.75% (variable), currently 10–11%

The most common financing vehicle for independent pharmacy acquisitions, SBA 7(a) loans cover up to $5M including goodwill, prescription file value, inventory, and working capital. Pharmacy-experienced SBA lenders understand prescription file collateral and DEA transfer requirements.

Pros

Low down payment requirement of 10–15% makes ownership accessible for pharmacist-buyers with limited capital
Prescription file and goodwill are eligible collateral, unlike most conventional business loans
10-year loan terms reduce monthly debt service, improving post-acquisition cash flow and DSCR

Cons

×DEA change-of-ownership approval and state board transfer can delay funding and closing timelines significantly
×Lenders require clean PBM contract review and may discount value if DIR fee exposure is high
×Personal guarantee required; variable rates create payment risk if prime rate rises post-close

Seller Financing (Seller Carry Note)

$100K–$800K6%–8% fixed, typically interest-only for 12 months then amortizing

Pharmacy sellers frequently carry 10–20% of the purchase price as a subordinated note, especially where prescription file retention risk or payer contract uncertainty creates valuation gaps. Seller carry signals confidence in patient base continuity and smooths SBA lender approval.

Pros

Bridges valuation gaps created by PBM reimbursement uncertainty or earnout disagreements between buyer and seller
Required by most SBA lenders as an equity injection substitute, reducing buyer's cash at close
Seller remains financially motivated to assist with patient retention and staff transition post-closing

Cons

×SBA standby requirements may restrict seller note repayment for 24 months, limiting seller liquidity
×Seller must remain creditworthy and willing to subordinate to SBA lender, which some retiring owners resist
×Adds complexity to deal structure; requires intercreditor agreement negotiation between all parties

Private Equity or Strategic Co-Investment

$500K–$3M equity checkTarget IRR of 20–30%; no fixed interest rate but equity dilution applies

PE-backed pharmacy platforms or strategic co-investors provide equity alongside SBA or conventional debt for specialty, compounding, or long-term care pharmacies with higher growth potential. Typically pursues roll-up strategies with EBITDA above $300K and identifiable add-on acquisition pipelines.

Pros

Provides growth capital beyond acquisition cost for technology, specialty licensing, or geographic expansion
PE partner brings operational expertise in PBM contract negotiation and compliance infrastructure
Reduces personal guarantee exposure for pharmacist-operators who partner rather than acquire independently

Cons

×Pharmacist-operators give up ownership percentage and autonomy, which conflicts with many independent pharmacy cultures
×PE partners typically require exit within 4–6 years, forcing a sale on a timeline the operator may not prefer
×Only viable for pharmacies with strong EBITDA, specialty revenue mix, and scalable operations; not suitable for most single-location retail pharmacies

Sample Capital Stack

$2,000,000 (includes prescription file, goodwill, inventory at cost, and equipment)

Purchase Price

~$18,500/month (SBA at 10.5% over 10 years) plus $1,400/month seller note interest-only; total ~$19,900/month

Monthly Service

1.25x DSCR required by SBA lender; pharmacy EBITDA of ~$300,000 annually supports debt service of approximately $239,000 per year

DSCR

SBA 7(a) loan: $1,600,000 (80%) | Seller carry note: $200,000 (10%) | Buyer equity injection: $200,000 (10%)

Model your own deal structure →

Lender Tips for Pharmacy Acquisitions

1Work with SBA lenders who have closed pharmacy transactions before — they understand prescription file collateral, DEA transfer timelines, and PBM contract review requirements that generalist lenders routinely mishandle.
2Request a trailing 24-month prescription volume report and active patient refill rate analysis before approaching lenders; these metrics directly influence how lenders assess post-acquisition revenue sustainability.
3Document DIR fee exposure clearly in your loan package — lenders increasingly stress-test pharmacy EBITDA against worst-case PBM reimbursement scenarios and will reduce loan proceeds if DIR risk is unquantified.
4Initiate DEA change-of-ownership registration and state pharmacy board license transfer early in the process; approval delays of 60–120 days can push closing timelines and create lender commitment expiration issues.

Frequently Asked Questions

Can I use an SBA loan to buy a pharmacy's prescription file and goodwill, or only hard assets?

Yes. SBA 7(a) loans explicitly cover intangible assets including prescription files, patient relationships, and goodwill, making them the preferred financing tool for independent pharmacy acquisitions where intangibles represent the majority of value.

How does PBM reimbursement risk affect what lenders will loan on a pharmacy acquisition?

Lenders underwrite to post-DIR-fee EBITDA and may haircut revenue projections if PBM contracts show rate compression trends. Pharmacies with specialty, compounding, or long-term care revenue receive better loan terms due to lower PBM dependency.

How much equity do I need to buy an independent pharmacy with SBA financing?

Typically 10–15% of the purchase price as equity injection. Seller carry of 10–20% often satisfies part of this requirement, meaning a buyer may contribute as little as 5–10% in personal cash at closing.

Will the DEA transfer process delay my pharmacy acquisition closing?

Yes. DEA change-of-ownership registration and state board approval typically take 60–120 days and must be coordinated with SBA funding timelines. Buyers should initiate applications immediately after letter of intent execution to avoid costly closing delays.

More Pharmacy Guides

Buy a Pharmacy Business →Valuation Guide →SBA Loan Guide →Deal Structure →Common Mistakes →SBA Calculator →Deal Structure Builder →

Ready to finance your Pharmacy acquisition?

DealFlow OS surfaces acquisition targets and helps you structure the deal. Free to join.

Start finding deals — free

No credit card required